Welcome to our dedicated page for Decoy Therapeutics SEC filings (Ticker: DCOY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoy Therapeutics Inc. filings document the company's public-company governance, capital structure, and corporate-status records following its name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. The filing record includes Form 8-K reports on certificate and bylaw amendments, the DCOY trading symbol, Nasdaq Capital Market listing matters, and amendments affecting common stock.
Proxy and meeting disclosures cover shareholder voting matters, including approval of an equity incentive plan and authorization for a reverse stock split. Additional filings describe the completed 1-for-12 reverse stock split, related security-holder rights changes, Nasdaq minimum bid price compliance, governance procedures, operating and financial results, and other material-event reporting for the issuer.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Lieber Jonathan I reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) director Jonathan I. Lieber received a grant of 2,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The award vests 100 percent on August 30, 2027, and brings his directly held beneficial ownership to 2,002 shares, adjusted for reverse stock splits effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 plan is reported for this award.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. PIERCE FREDERICK II reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that Chief Executive Officer Frederick Pierce II received a grant of 33,455 shares of restricted common stock on August 31, 2026 under the company’s 2026 Equity Incentive Plan. 25% of this restricted stock vested immediately, with the balance vesting in approximately equal monthly installments over the next 36 months. Following the grant, he beneficially owned 34,844 shares of common stock, a figure adjusted to reflect a reverse stock split effective on March 6, 2026.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Marschel Peter Klaus reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that Chief Business Officer Marschel Peter Klaus received a grant of 3,900 shares of Common Stock on August 31, 2026 as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. According to the terms, 25 percent of the restricted stock vested immediately, with the remaining shares scheduled to vest in approximately equal monthly installments over the next 36 months. Following this award, he holds 3,900 shares directly. No Rule 10b5-1 trading plan is reported for this grant.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Rosenblum Mark J reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that Chief Financial Officer Mark J. Rosenblum received a grant of 9,682 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. Twenty-five percent vested immediately and the rest will vest in approximately equal monthly increments over the next 36 months. Following this award, he beneficially owns 11,363 shares, with the share count adjusted for reverse stock splits effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 trading plan is reported.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Hibner Barbara Louise reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that Chief Scientific Officer Barbara Louise Hibner received a grant of 4,216 shares of common stock as restricted stock under the company’s 2026 Equity Incentive Plan on August 31, 2026. 25% of these shares vested immediately, with the balance vesting in approximately equal monthly installments over the next 36 months. Following this award, she directly holds 4,216 shares of common stock.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. HANISH ARNOLD C reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Arnold C. Hanish received a grant of 3,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The restricted stock will vest 100 percent on August 30, 2027. Following this award, Hanish beneficially owns 3,418 common shares, adjusted to reflect the reverse stock split effective on March 6, 2026. No Rule 10b5-1 trading plan is reported for this award.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Lammers Paul reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Paul Lammers received a grant of 2,000 shares of Common Stock as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan on August 31, 2026. The grant carries a vesting schedule under which 100 percent will vest on August 30, 2027. Following this award, Lammers is reported to beneficially own 2,001 shares of Decoy Therapeutics common stock on a direct basis, with this post-transaction amount adjusted to reflect reverse stock splits that became effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 trading plan is reported for this transaction.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Burleson Tess reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Tess Burleson received a grant of 2,000 shares of common stock as restricted stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The grant vests 100 percent on August 30, 2027, and Burleson now beneficially owns 2,002 shares directly, with the post-transaction amount adjusted for reverse stock splits effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 trading plan is reported for this award.
Decoy Therapeutics Inc. (DCOY) reported that director William K. McVicar received a grant of 3,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The award was granted at $0.00 per share and represents a compensation-related acquisition rather than an open-market purchase.
According to the grant terms, 100 percent of the restricted stock will vest on August 30, 2027. Following this award and after adjustments for prior reverse stock splits effective on August 15, 2025 and March 6, 2026, McVicar is reported to beneficially own 3,002 shares of Decoy Therapeutics common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Gauthier Patricia G. reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Patricia G. Gauthier received a grant of 2,000 shares of Common Stock on August 31, 2026. The award was granted at $0.00 per share as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan and 100 percent will vest on August 30, 2027. Following this grant, she directly holds 2,000 shares.